BiotechTube

Cefazolin IV + Linezolid IV + Vancomycin (IV)

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bacteremia

Conditions

Bacteremia, Gram-Positive Bacterial Infections

Trial Timeline

Sep 1, 2005 → Sep 1, 2006

NCT ID
NCT00108433

About Cefazolin IV + Linezolid IV + Vancomycin (IV)

Cefazolin IV + Linezolid IV + Vancomycin (IV) is a phase 3 stage product being developed by Pfizer for Bacteremia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00108433. Target conditions include Bacteremia, Gram-Positive Bacterial Infections.

What happened to similar drugs?

2 of 4 similar drugs in Bacteremia were approved

Approved (2) Terminated (2) Active (1)
✅Daptomycin + ComparatorMerckApproved
✅Vancomycin + DaptomycinMerckApproved
❌Ceftolozane-Tazobactam + MeropenemMerckPhase 3
🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00108433Phase 3Terminated

Competing Products

9 competing products in Bacteremia

See all competitors
ProductCompanyStageHype Score
Daptomycin + ComparatorMerckApproved
43
Daptomycin for InjectionMerckPhase 2
35
Vancomycin + DaptomycinMerckApproved
35
Ceftolozane-Tazobactam + MeropenemMerckPhase 3
32
Aurexis®Bristol Myers SquibbPhase 2
35
ceftobiprole medocarilBasilea PharmaceuticaPhase 2
21
Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3
34
AP-SA02Armata PharmaceuticalsPhase 1/2
22
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIXBiotechPhase 1/2
22